Carcinoma, Hepatocellular Clinical Trial
Official title:
Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas
Background: The association of transcatheter arterial chemotherapy infusion (TAC) with
percutaneous ablation (PT) has been introduced as a method to increase the ablative zone. The
aim of this study was to evaluate the efficacy of PT and TAC performed in a single session
for HCCs between 30 and 50 mm or oligonodular up to 30 mm.
Methods: Thirty patients with a histologically proven HCC, uninodular between 30 and 50 mm or
oligonodular (n≤3) up to 30 mm, treatment-naïve and non-metastatic, received combination
treatment ("PT+TAC group"). A "control" group consisted of 34 patients with uninodular HCC up
to 30 mm without any poor prognostic criteria treated with PT alone ("PT group").
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03289533 -
A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
|
Phase 1 | |
| Terminated |
NCT01141478 -
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
|
N/A | |
| Recruiting |
NCT05580835 -
PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma
|
N/A | |
| Active, not recruiting |
NCT05389527 -
Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma
|
Phase 2 | |
| Not yet recruiting |
NCT04560751 -
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong)
|
||
| Withdrawn |
NCT02939807 -
A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT01915602 -
Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Completed |
NCT04970212 -
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
|
||
| Recruiting |
NCT02403544 -
Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma
|
Phase 1 | |
| Completed |
NCT01897038 -
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
|
Phase 1 | |
| Terminated |
NCT01337492 -
Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
|
Phase 0 | |
| Terminated |
NCT01020812 -
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01012011 -
Regulatory Post Marketing Surveillance Study on Nexavar®
|
N/A | |
| Completed |
NCT01003015 -
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT00559455 -
Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma
|
Phase 2 | |
| Recruiting |
NCT00384800 -
A Phase II Study of Tegafur/Uracil (UFUR®)Plus Thalidomide for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma (HCC)
|
Phase 2 | |
| Terminated |
NCT00582400 -
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
|
Phase 2 | |
| Completed |
NCT00056992 -
Testing of ADI-PEG in Hepatocellular Carcinoma
|
Phase 2 | |
| Completed |
NCT02859324 -
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
|
Phase 1/Phase 2 | |
| Terminated |
NCT02439008 -
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
|
N/A |